サルコマにおける高転移性要素発現は,免疫インフィルトレートの増加と,免疫療法後の改善と関連しています
Benjamin A Nacev1,2, Martina Bradic3, Hyung Jun Woo3
1Department of Medicine, University of Pittsburgh, Pittsburgh, Pennsylvania, USA nacevba@upmc.edu.
Journal for immunotherapy of cancer
|September 5, 2025
まとめ
トランスポーザブル要素 (TEs) とIKZF1発現は,免疫チェックポイント阻害 (ICI) で治療されたサルコマ患者の免疫浸透とより良い結果を予測します. これらの発見は,TEsとIKZF1を,ICIの有効性を改善するための潜在的なバイオマーカーと治療標的として示唆しています.
科学分野:
- 腫瘍学
- 免疫学
- 遺伝学
背景:
- サルコマにおける免疫チェックポイント阻害 (ICI) 反応は限られ,多様である.
- ICIの結果に影響を与える要因を特定することは,有効性と患者選択の改善に不可欠です.
- 移植可能な要素 (TEs) は表遺伝的に静止され,抗腫瘍免疫を活性化することができます.
研究 の 目的:
- 移植可能要素 (TE) の発現がICIのアウトカムとサルコマサブタイプにおける免疫インフィルトラートに影響を与えるかどうかを調査する.
- サルコマの免疫浸透を予測するエピジェネティック調節遺伝子の役割を決定する.
- ICI治療を受けているサルコマ患者のTEとIKZF1発現と臨床結果の相関性を調べる.
主な方法:
- ICI試験のサルコマバイオプシー (n=67) のトランスクリプトミックのデータを分析した.
- 機械学習 (ラソペナライズされたロジスティック回帰) は免疫状態の予測要因を特定した.
- TE/ IKZF1発現,免疫浸透,経路,および臨床結果の間の相関は複数のコホートで評価された.
主要な成果:
- TEとエピジェネティックレギュレータの発現は,サルコマにおける免疫状態の向上を有意に予測した.
- TEサブファミリーとIKZF1発現は,免疫浸透と炎症経路と正に相関する重要な予測因子でした.
- TEとIKZF1発現の増加は,全生存期および進行性生存期を含む改善された臨床結果と関連していました.
結論:
- TEとIKZF1の発現は,腫瘍の免疫浸透とサーコマのICI治療結果を予測する有望なバイオマーカーです.
- TEとIKZF1を治療目標として探求するためのさらなる翻訳研究が正当化されています.
- これらの発見は,患者の選択を最適化し,サルコマの治療におけるICIの有効性を改善するのに役立ちます.
関連する概念動画
01:27Tumor Immunotherapy
658
Immunotherapy is a treatment that boosts or manipulates the immune system to fight diseases, including cancer. For instance, by stimulating an immune response through vaccinations against viruses that cause cancers, like hepatitis B virus and human papillomavirus, these diseases can be prevented. Nonetheless, some cancer cells can avoid the immune system due to their rapid mutation and division. The immune response to many cancers involves three phases: elimination, equilibrium, and escape.
658
02:39lncRNA - Long Non-coding RNAs
8.9K
In humans, more than 80% of the genome gets transcribed. However, only around 2% of the genome codes for proteins. The remaining part produces non-coding RNAs which includes ribosomal RNAs, transfer RNAs, telomerase RNAs, and regulatory RNAs, among other types. A large number of regulatory non-coding RNAs have been classified into two groups depending upon their length – small non-coding RNAs, such as microRNA, which are less than 200 nucleotides in length, and long non-coding RNA...
8.9K
02:17The Tumor Microenvironment
6.8K
Every normal cell or tissue is embedded in a complex local environment called stroma, consisting of different cell types, a basal membrane, and blood vessels. As normal cells mutate and develop into cancer cells, their local environment also changes to allow cancer progression. The tumor microenvironment (TME) consists of a complex cellular matrix of stromal cells and the developing tumor. The cross-talk between cancer cells and surrounding stromal cells is critical to disrupt normal tissue...
6.8K
03:18Non-LTR Retrotransposons
11.8K
As the name suggests, non-LTR retrotransposons lack the long terminal repeats characteristic of the LTR retrotransposons. Additionally, both LTR and non-LTR retrotransposons use distinct mechanisms of mobilization. Non-LTR retrotransposons are further divided into two classes - Long interspersed nuclear elements (LINEs) and short interspersed nuclear elements (SINEs), both of which occur abundantly in most mammals, including humans. Some of the active non-LTR retrotransposons in humans are L1...
11.8K
01:03Rous Sarcoma Virus (RSV) and Cancer
5.4K
Rous Sarcoma virus or RSV was discovered by F. Peyton Rous in the year 1911 as a filterable transmissible agent that could cause tumors in chickens. He won a Nobel Prize for this discovery in 1966. His experiments clearly demonstrated that some cancers could be caused by infectious agents and led to the discovery of many more cancer-causing viruses in animals as well as humans.
RSV is a retrovirus that contains two copies of a plus-strand RNA genome. Its genome consists of four main open...
RSV is a retrovirus that contains two copies of a plus-strand RNA genome. Its genome consists of four main open...
5.4K